These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 37442065)
21. Clinically used selective oestrogen receptor modulators increase LDL receptor activity in primary human lymphocytes. Cerrato F; Fernández-Suárez ME; Alonso R; Alonso M; Vázquez C; Pastor O; Mata P; Lasunción MA; Gómez-Coronado D Br J Pharmacol; 2015 Mar; 172(5):1379-94. PubMed ID: 25395200 [TBL] [Abstract][Full Text] [Related]
22. Mechanisms of the hepatoprotective effects of tamoxifen against drug-induced and chemical-induced acute liver injuries. Yoshikawa Y; Miyashita T; Higuchi S; Tsuneyama K; Endo S; Tsukui T; Toyoda Y; Fukami T; Nakajima M; Yokoi T Toxicol Appl Pharmacol; 2012 Oct; 264(1):42-50. PubMed ID: 22841776 [TBL] [Abstract][Full Text] [Related]
23. Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo. Eigeliene N; Kangas L; Hellmer C; Kauko T; Erkkola R; Härkönen P Menopause; 2016 Jul; 23(7):719-30. PubMed ID: 27163517 [TBL] [Abstract][Full Text] [Related]
24. Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites. Weatherman RV; Clegg NJ; Scanlan TS Chem Biol; 2001 May; 8(5):427-36. PubMed ID: 11358690 [TBL] [Abstract][Full Text] [Related]
25. Estrogen and selective estrogen receptor modulators exert neuroprotective effects and stimulate the expression of selective Alzheimer's disease indicator-1, a recently discovered antiapoptotic gene, in human neuroblast long-term cell cultures. Benvenuti S; Luciani P; Vannelli GB; Gelmini S; Franceschi E; Serio M; Peri A J Clin Endocrinol Metab; 2005 Mar; 90(3):1775-82. PubMed ID: 15585566 [TBL] [Abstract][Full Text] [Related]
26. Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells. Kallio A; Guo T; Lamminen E; Seppänen J; Kangas L; Väänänen HK; Härkönen P Mol Cell Endocrinol; 2008 Jul; 289(1-2):38-48. PubMed ID: 18455292 [TBL] [Abstract][Full Text] [Related]
27. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells. Liu H; Park WC; Bentrem DJ; McKian KP; Reyes Ade L; Loweth JA; Schafer JM; Zapf JW; Jordan VC J Biol Chem; 2002 Mar; 277(11):9189-98. PubMed ID: 11751902 [TBL] [Abstract][Full Text] [Related]
29. ERE-independent ERalpha target genes differentially expressed in human breast tumors. Glidewell-Kenney C; Weiss J; Lee EJ; Pillai S; Ishikawa T; Ariazi EA; Jameson JL Mol Cell Endocrinol; 2005 Dec; 245(1-2):53-9. PubMed ID: 16298037 [TBL] [Abstract][Full Text] [Related]
30. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs). Musa MA; Khan MO; Cooperwood JS Curr Med Chem; 2007; 14(11):1249-61. PubMed ID: 17504144 [TBL] [Abstract][Full Text] [Related]
31. Selective estrogen-receptor modulators suppress microglial activation and neuronal cell death via an estrogen receptor-dependent pathway. Ishihara Y; Itoh K; Ishida A; Yamazaki T J Steroid Biochem Mol Biol; 2015 Jan; 145():85-93. PubMed ID: 25305410 [TBL] [Abstract][Full Text] [Related]
32. Raloxifene is a Female-specific Proteostasis Therapeutic in the Spinal Cord. Jenkins EC; Casalena G; Gomez M; Zhao D; Kenny TC; Shah N; Manfredi G; Germain D Endocrinology; 2021 Feb; 162(2):. PubMed ID: 33269387 [TBL] [Abstract][Full Text] [Related]
33. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects. Muchmore DB Oncologist; 2000; 5(5):388-92. PubMed ID: 11040275 [TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo molecular imaging of estrogen receptor α and β homo- and heterodimerization: exploration of new modes of receptor regulation. Paulmurugan R; Tamrazi A; Massoud TF; Katzenellenbogen JA; Gambhir SS Mol Endocrinol; 2011 Dec; 25(12):2029-40. PubMed ID: 22052998 [TBL] [Abstract][Full Text] [Related]
35. Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance. Bergamaschi A; Katzenellenbogen BS Oncogene; 2012 Jan; 31(1):39-47. PubMed ID: 21666713 [TBL] [Abstract][Full Text] [Related]
36. Comparing the effects of 17β-oestradiol and the selective oestrogen receptor modulators, raloxifene and tamoxifen, on prepulse inhibition in female rats. Gogos A; van den Buuse M Schizophr Res; 2015 Nov; 168(3):634-9. PubMed ID: 25979306 [TBL] [Abstract][Full Text] [Related]
37. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. Michael H; Härkönen PL; Kangas L; Väänänen HK; Hentunen TA Br J Pharmacol; 2007 Jun; 151(3):384-95. PubMed ID: 17420779 [TBL] [Abstract][Full Text] [Related]
38. The effects of alone and combination tamoxifen, raloxifene and estrogen on lipid profile and atherogenic index of ovariectomized type 2 diabetic rats. Ebrahimi MN; Khaksari M; Sepehri G; Karam GA; Raji-Amirhasani A; Azizian H Life Sci; 2020 Dec; 263():118573. PubMed ID: 33058909 [TBL] [Abstract][Full Text] [Related]
39. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. Park WC; Jordan VC Trends Mol Med; 2002 Feb; 8(2):82-8. PubMed ID: 11815274 [TBL] [Abstract][Full Text] [Related]
40. The cardiovascular effects of selective estrogen receptor modulators. Christodoulakos GE; Lambrinoudaki IV; Botsis DC Ann N Y Acad Sci; 2006 Dec; 1092():374-84. PubMed ID: 17308162 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]